Adverse events: Clinically important specific adverse events · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per NIMH 1987, or with…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: Clinically important specific adverse events · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per NIMH 1987, or with…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: General ‐ serious · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ weight increase compared with ORAL ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
RISPERIDONE DEPOT may leads to lower adverse events: Specific ‐ weight increase compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ prolactin‐related compared with ORAL RISPERIDONE (moderate certainty).
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Adverse events: General ‐ serious · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious Recorded at each compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse events: Movement disorder ‐ any extra pyramidal symptom · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptom compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term · patients with schizophrenia
1 finding from 1 review
Weight gain · patients with schizophrenia
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Specific ‐ prolactin‐related Reported by… compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse events: General ‐ serious Unclear how these events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General ‐ serious Unclear how these events were… compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐… compared with ORAL RISPERIDONE (moderate certainty).
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review